|[February 22, 2013]
Blaze Bioscience Announces Completion of Series A Financing - Brings Total Investment to $9.8 Million
SEATTLE --(Business Wire)--
Bioscience, Inc., a biotechnology company dedicated to developing
innovative products to improve the lives of cancer patients, today
announced the completion of a Series A financing totaling $8.5 million
and bringing the total funds raised since inception to $9.8 million. The
round was raised from individual investors, including physicians and
prominent biotech executives. A majority of the investors involved in
Blaze's seed funding round increased their level of participation. The
funding will support the advancement of Blaze's Tumor PaintTM
product candidate, BLZ-100, into clinical development for use in surgery
in multiple solid tumor types. The resources have also supported the
expansion of Blaze's leadership team and establishment of corporate
headquarters, including laboratory space, in the South Lake Union area
"We have a dedicated group of investors who share our vision of bringing
light into tumor cells so that surgeons can see them in real time," said
Dr. Jim Olson, Blaze Bioscience Co-Founder and Board Member.
Blaze Bioscience's Tumor Paint technology is designed to provide
real-time, high-resolution visualization of a broad array of solid
tumors by binding to and illuminating cancer cells to aid in surgical
removal. BLZ-100, the lead product candidate incorporating Tumor Paint
technology, combines a targeting peptide and a fluorescent beacon.
BLZ-100 is entering toxicology studies, and a Phase 1 clinical trial
exploring safety and effective imaging dose is planned in cancer
patients with multiple tumor tyes.
New appointments to the Blaze leadership team include Dennis Miller,
Ph.D., as Senior Vice President of Development, and Claudia Jochheim,
Ph.D., as Senior Director of Process Development and Manufacturing.
"With this additional funding and the added expertise of Dr. Miller and
Dr. Jochheim, we plan to move our first Tumor Paint product candidate,
BLZ-100, into the clinic," said Heather Franklin, Co-Founder, President
and Chief Executive Officer of Blaze Bioscience. "Both Dennis and
Claudia have extensive experience with moving products into clinical
trials and beyond."
Dr. Miller brings 20 years of experience in the pharmaceutical and
biotechnology research and development space. Most recently, Dr. Miller
served as Senior Vice President of Research and Preclinical Development
at ZymoGenetics, having responsibility spanning the company's discovery,
preclinical development, bioprocess development and clinical trial
laboratory support activities. Prior to ZymoGenetics, he held research
and development positions at Seattle Genetics, Amgen, Nycomed and
Sterling Winthrop. Dr. Miller has contributed to the preclinical and
clinical development of over 20 therapeutics, including Adcetris®
and IL-21 for oncology, and Interferon lambda, Nplate® and
Kineret® for virology and chronic autoimmune disorders.
Dr. Jochheim is a biochemist with more than 20 years of experience in
the biotechnology industry. Prior to joining Blaze Bioscience, Dr.
Jochheim was an independent consultant. She formerly held strategic
leadership positions as Senior Director/Director of Analytical
Biochemistry and Formulations in Process Development at Seattle
Genetics, where she built and led groups of up to 30 scientists. At
Seattle Genetics, Dr. Jochheim played a key role in moving the
antibody-drug-conjugate Adcetris® from development to the
market. Prior to Seattle Genetics, she was Director of Analytical
Biochemistry at Corixa and a Senior Scientist/Scientist at Immunex and
Amgen, where she was project leader for several development projects,
including Enbrel® and Vectibix®. Her experience
includes all aspects of technology transfer to contract manufacturing
organizations and preparation of product-related CMC regulatory filings
Blaze Bioscience opened its headquarters, including laboratory and
office space, at the Fairview Research Center in the South Lake Union
area of Seattle.
About Blaze Bioscience
Blaze Bioscience, Inc. is a Seattle-based, privately-held biotechnology
company dedicated to developing products that assist physicians in their
quest to improve the lives of cancer patients. The company was founded
in 2010 to develop and commercialize the Tumor Paint technology, which
has potential applications in a broad array of solid tumor cancers.
Tumor Paint technology is designed to provide real-time, high-resolution
intraoperative visualization of cancer cells, enabling better detection
and more complete and precise surgical removal of cancer. The first
Tumor Paint product candidate, BLZ-100, is under development for cancer
surgery in multiple solid tumor types. For additional information,
please visit www.blazebioscience.com.
[ Back To Technology News's Homepage ]